 OKYO Pharma Ltd LSE:OKYO, NASDAQ:OKYO said it had filed an investigational new drug application with the US authorities for OK-101, its putative treatment for dry eye disease. It plans to carry out a phase II trial after being allowed to skip the initial safety phase by Food Drug Administration. 